Overview
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Status:
NOT_YET_RECRUITING
NOT_YET_RECRUITING
Trial end date:
2029-10-01
2029-10-01
Target enrollment:
Participant gender: